Skip to main content

Advertisement

Table 9 Sensitivity analysis results for the impact of each parameter on cost-effectiveness

From: Cost-effectiveness analysis of oral anti-viral drugs used for treatment of chronic hepatitis B in Turkey

Parameter Change New value   Total cost (TL) YLL Cost difference (TL) Year difference  
Age = 50 years   50 TDF 119,604 1.302    
    ETV-TDF 161,642 1.347 42,037 0.045  
    ETV 162,115 1.347 42,511 0.046  
    LdT-TDF 138,182 1.923 18,577 0.622  
    3TC-TDF 132,157 2.028 12,552 0.726  
    LdT 151,059 2.581 31,455 1.280  
    3TC 147,245 4.109 27,640 2.807  
    TDF 119,604 2.987    
    ETV-TDF 161,642 3.088 42,037 0.101  
    ETV 162,115 3.089 42,511 0.102  
Age = 30 years   30 LdT-TDF 138,182 4.429 18,577 1.442  
    3TC-TDF 132,157 4.621 12,552 1.634  
    LdT 151,059 5.954 31,455 2.967  
    3TC 147,245 9.453 27,640 6.465  
    TDF 119,411 2.025    
    ETV-TDF 161,353 2.079 41,943 0.054  
    ETV 161,826 2.079 42,416 0.055  
HBeAg (−) rate 25 % increase 88 % LdT-TDF 132,215 2.656 12,804 0.631  
    3TC-TDF 127,731 2.907 8320 0.882  
    LdT 137,643 3.152 18,233 1.128  
    3TC 128,004 5.124 8593 3.099  
    TDF 119,798 2.096    
    ETV-TDF 161,930 2.183 42,132 0.087  
    ETV 162,404 2.183 42,606 0.088  
HBeAg (−) rate 25 % decrease 53 % LdT-TDF 144,149 3.445 24,351 1.349  
    3TC-TDF 136,582 3.487 16,784 1.391  
    LdT 164,475 5.045 44,677 2.949  
    3TC 166,486 7.907 46,688 5.811  
    TDF 119,573 2.055    
    ETV-TDF 161,642 2.131 42,068 0.076  
    ETV 162,115 2.131 42,542 0.076  
TDF: virologic response 48th week in HBeAg (−) 25 % increase 100.0 % LdT-TDF 138,176 3.049 18,603 0.994  
    3TC-TDF 132,148 3.196 12,574 1.140  
    LdT 151,059 4.099 31,486 2.043  
    3TC 147,245 6.515 27,672 4.460  
    TDF 119,711 2.078    
    ETV-TDF 161,642 2.131 41,931 0.053  
    ETV 162,115 2.131 42,404 0.053  
TDF: Virologic response 48th week in HBeAg (−) 25 % decrease 69.9 % LdT-TDF 138,202 3.054 18,491 0.976  
    3TC-TDF 132,186 3.202 12,475 1.124  
    LdT 151,059 4.099 31,348 2.021  
    3TC 147,245 6.515 27,534 4.437  
    TDF 119,538 2.049    
    ETV-TDF 161,642 2.131 42,103 0.082  
    ETV 162,115 2.131 42,577 0.082  
TDF: Virologic response 48th week in HBeAg (+) 25 % increase 95.2 % LdT-TDF 138,153 3.044 18,614 0.996  
    3TC-TDF 132,118 3.190 12,580 1.141  
    LdT 151,059 4.099 31,521 2.050  
    3TC 147,245 6.515 27,707 4.467  
    TDF 119,671 2.072    
    ETV-TDF 161,642 2.131 41,971 0.059  
    ETV 162,115 2.131 42,444 0.060  
TDF: Virologic response 48th week in HBeAg (+) 25 % decrease 57.1 % LdT-TDF 138,211 3.056 18,540 0.985  
    3TC-TDF 132,195 3.204 12,524 1.133  
    LdT 151,059 4.099 31,388 2.027  
    3TC 147,245 6.515 27,574 4.444  
    TDF 140,826 2.060    
    ETV-TDF 161,879 2.131 1053 0.070  
    ETV 162,115 2.131 1289 0.071  
TDF annual drug cost 25 % decrease 2796 TL LdT-TDF 144,943 3.050 4117 0.990  
    3TC-TDF 147,174 3.197 6348 1.137  
    LdT 151,059 4.099 0233 2.038  
    3TC 147,245 6.515 6419 4.455  
    TDF 98,383 2.060    
    ETV-TDF 161,405 2.131 63,022 0.070  
    ETV 162,115 2.131 63,732 0.071  
TDF annual drug cost 25 % decrease 1677 TL LdT-TDF 131,421 3.050 33,038 0.990  
    3TC-TDF 117,139 3.197 18,756 1.137  
    LdT 151,059 4.099 52,676 2.038  
    3TC 147,245 6.515 48,862 4.455  
  1. Tenofovir dominates all comparisons in all scenarios